BESTOW: A Phase 2, Multicenter, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Tegoprubart in Patients Undergoing Kidney Transplantation
The BESTOW Study: Safety and Efficacy of Tegoprubart in Patients Undergoing Kidney Transplantation
Sponsor: Eledon Pharmaceuticals, Inc.
Enrolling: Male and Female Patients
IRB Number: AAAU6803
U.S. Govt. ID: NCT05983770
Contact: Transplant Clinical Research Center: / tcrcstudyreferral@cumc.columbia.edu
Additional Study Information: The purpose of this study is to determine if an investigational drug called tegoprubart (also known as AT1501) is safe and effective in preventing rejection in patients who are undergoing a kidney transplant for the first time. Participants will be randomly assigned to tegoprubart or standard treatment with tacrolimusat the time of transplant. If you have any questions regarding this study, please contact the Transplant Clinical Research Center (TCRC).
Investigator
Lloyd Ratner, MD, MPH, FACS
Do You Qualify?
Are you at least 18 years old? Yes No
Are you on the waiting list to receive your first kidney transplant? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Transplant Clinical Research Center
tcrcstudyreferral@cumc.columbia.edu

This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE